• Sales revenue of $5.5 billion, up 180.5%
• Statutory NPAT attributable to owners of $379.8 million, up 22.6%
• Interim dividend of 2.0 cents per share, fully franked

Sigma Healthcare Limited has reported its half year financial results for the period ended 31 December 2025. The results reflect the impact of the merger between Sigma and Chemist Warehouse, which was completed on 12 February 2025. The comparative results for the half year ended 31 December 2024 represent Chemist Warehouse's results only. Key highlights include sales revenue of $5.5 billion, up 180.5% from the prior corresponding period, and statutory net profit after tax (NPAT) attributable to owners of $379.8 million, up 22.6%. The company has declared an interim dividend of 2.0 cents per share, fully franked. The merger has resulted in changes to Sigma's financial reporting, with ASIC granting relief to allow the company to report based on a notional financial year ending 30 June, aligning with Chemist Warehouse's previous reporting period. The directors have provided a review of the Group's operations, highlighting the strong financial performance and integration progress following the merger.

The company has not provided any high-importance, price-sensitive forward-looking financial metrics in the announcement.